Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoBRAF: Neoadjuvant Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Colorectal Cancer
NCT05510895Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib, cetuximab in colorectal cancer (CRC), sponsored by AIO-Studien. Started Sep 2022; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05510895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510895.